Human Vaccines & Immunotherapeutics

ISSN: 2164-5515 (Print) 2164-554X (Online) Journal homepage: http://www.tandfonline.com/loi/khvi20

Letter from the Editor: Pneumococcal conjugate vaccine Ronald Ellis To cite this article: Ronald Ellis (2014) Letter from the Editor: Pneumococcal conjugate vaccine, Human Vaccines & Immunotherapeutics, 10:9, 2754-2754, DOI: 10.4161/21645515.2014.980103 To link to this article: http://dx.doi.org/10.4161/21645515.2014.980103

Accepted author version posted online: 31 Oct 2014.

Submit your article to this journal

Article views: 31

View related articles

View Crossmark data

Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=khvi20 Download by: [180.180.0.123]

Date: 05 November 2015, At: 18:57

LETTER FROM THE EDITOR Human Vaccines & Immunotherapeutics 10:9, 2754; September 2014; © 2014 Taylor & Francis Group, LLC

Letter from the Editor: Pneumococcal conjugate vaccine Ronald Ellis*

Downloaded by [180.180.0.123] at 18:57 05 November 2015

7 July 2014 Human Vaccines & Immunotherapeutics regularly publishes Special Features on topics of broad interest. Our May issue featured four commentaries on pneumococcal conjugate vaccines (PCV). Two of these commentaries (link to Fedson, link to Hollingsworth) addressed general aspects of clinical protection in older subjects following PCV vaccination. The other two of these commentaries (link to Shapiro, link to Musher) discussed clinical protection as well as the recent very large Phase 3 CAPITA clinical trial, which showed that the leading PCV (Prevnar, Pfizer) elicits protection against pneumococcal pneumonia and invasive pneumococcal disease caused by vaccine serotypes in elderly subjects. It should be noted that the latter commentaries were based on top-line results in a presentation at an international conference and not on the full set of clinical data, which will not be publically available until after the publication of the clinical research article on the CAPITA trial. Pfizer would like to write their own commentary in HV&I on this CAPITA trial, which they can do fully only after their original clinical research article on CAPITA has been accepted for publication. Ronald Ellis PhD Editor-in-Chief

*Correspondence to: Ronald Ellis; [email protected] Submitted: 07/07/2014; Accepted: 07/07/2014 http://dx.doi.org/10.4161/21645515.2014.980103

2754

Human Vaccines & Immunotherapeutics

Volume 10 Issue 9

Letter from the Editor: pneumococcal conjugate vaccine.

Letter from the Editor: pneumococcal conjugate vaccine. - PDF Download Free
395KB Sizes 2 Downloads 10 Views